TARGETING NEUROENDOCRINE PATHWAYS IN MAJOR DEPRESSION: A PHARMACOLOGICAL REVIEW (WPA-WCP 2026) - Oct 15, 2026 - Abstract #SO169; Pres time: Sep 24, 2026; 04:05 PM - 04:10 PM; Location: Station 03; "Mifepristone has demonstrated symptom reduction in psychotic depression, while other agents have shown inconsistent results...Allopregnanolone derivatives, such as brexanolone and zuranolone, can rapidly alleviate postpartum depression. Neuroendocrine dysregulation contributes to the pathogenesis of MDD. Neuroendocrine dysregulation contributes to the pathogenesis of MDD. Modulating neuroendocrine pathways may represent a promising approach to improving patient outcomes in depressive episodes. Further studies are needed to confirm these findings, as well as to assess long-term efficacy, safety, and tolerability."
Review • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry
|